Virogin Biotech

Oncolytic Virotherapy

Also 5 trials Clin1 multiple cancers; VG201 Clin1 solid tumors; VG203 Clin0 solid tumors; VG301 Clin0 solid tumors; multiple programs RD oncology

Virogin Biotech is a clinical-stage immuno-oncology company aiming to produce therapeutics that possess robust and durable anti-tumor responses against solid tumors, such as oncolytic virotherapy and mRNA vaccines. Their mission is to provide novel treatments that enhance systemic antitumor immunity to patients with high unmet medical needs. Current limitations of cancer vaccines include an immunosuppressive tumor microenvironment and vaccine resistance. Virogin’s oncolytic virotherapies attempt to overcome these obstacles through the delivery of multiple immunomodulatory payloads and increasing the release of tumor neoantigens. These therapeutics then are able to not only selectively kill cancer cells, but also simultaneously activate and boost the anti-tumor immune response, in aims to improve patient outcomes.

Jobs:

News: